News

JDRF welcomes TGA approval on Pfizer vaccine for children aged 12-15

JDRF
JDRF
July 23, 2021

JDRF Australia welcomes the announcement that the Therapeutic Goods Administration (TGA) has approved the Pfizer COVID-19 vaccine for children aged 12-15.

We look forward to the final decision from the Australian Technical Advisory Group on Immunisation (ATAGI) to prioritise children with underlying conditions, including type 1 diabetes, and include them immediately in the vaccine rollout.

COVID-19 is a particular concern for the type 1 diabetes community, and we applaud this new development for giving young people a way to protect themselves against the devastating effects of the disease. 

Commenting on the announcement, JDRF Australia Chief Scientific Officer Dr Dorota Pawlak said “this is a great step forward for many families living with type 1 diabetes, offering young people an opportunity to protect themselves and others against COVID-19. We thank all the researchers, clinical trial participants and government groups who have made this new development possible.”

JDRF
JDRF